Biosafety assays for the diagnosis and prediction of drug-related complement pathology

Projektinformationen

Biosafety

ID Finanzhilfevereinbarung: 952520

DOI

10.3030/952520

Projekt abgeschlossen

EK-Unterschriftsdatum 6 Juli 2020

Startdatum 1 September 2020

Enddatum 31 August 2023

Finanziert unter

• Twinning of research institutions

Gesamtkosten

€ 900 000,00

EU-Beitrag

€ 900 000,00

Koordiniert durch

SEMMELWEIS EGYETEM
Hungary

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Leistungen

Documents, reports (8)

“BIOSAFETY” Joint Summer School (A and B)

A joint summer school will be organised in Budapest

Report about the meetings with interest groups from industry

Meetings with interest groups from industry will be reported

KPIs definition for “BIOSAFETY”

This list of putative KPIs will be thoroughly discussed with the expert partnering institutions and a final list will be compiled

Impact assessment by the end of the project and forecast of the following 3-year period

Impact assessment will be performed in a 3year window by the end of the project

"„The industrial day"" and ""Knowledge Transfer Zone"" through meetings between research institutions and enterprises"

Experts from the partnering institutions will be invited to provide inspirational lectures and topic related events to stimulate brainstormingExperts from the partnering institutions will be invited to provide inspirational lectures and topic related events to stimulate brainstorming

Impact assessment in the 3-year period prior to “BIOSAFETY” for all KPIs

Impact assessment will be performed in a 3year window at the begining of the project

Publication history of Semmelw in the last 3 years
“BIOSAFETY” Thematic Workshop (A and B)

Thematic workshop for example biosafety markers un indispensable tool to predict unwanted side effects relevant to BIOSAFETY project will be organised

Open Research Data Pilot (2)

First data Management Plan
Final Data Management Plan

Websites, patent fillings, videos etc. (1)

Development of the project logo/brand and brochure/flyer

Developing a project logo and setting up a project website are two critical steps which will pave the way for an effective Public Relations PR strategy for BIOSAFETYA brochure and flyer will also be developed in the first year of the project to support the dissemination of BIOSAFETY in different events They will be revised when needed

Veröffentlichungen

Peer reviewed articles (15)

Effect of the Addition of Alginate and/or Tetracycline on Brushite Cement Properties

Autoren: Claudia Morilla, Elianis Perdomo, Ana Karla Hernández, Ramcy Regalado, Amisel Almirall, Gastón Fuentes, Yaima Campos Mora, Timo Schomann, Alan Chan, Luis J. Cruz
Veröffentlicht in: Molecules, Ausgabe 26/11, 2021, Seite(n) 3272, ISSN 1420-3049
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/molecules26113272

Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy

Autoren: Yang Hao,Chih Kit Chung,Zhenfeng Yu,Ruben V. Huis in ‘t Veld,Ferry A. Ossendorp,Peter ten Dijke,and Luis J. Cruz.
Veröffentlicht in: Pharmaceutics, 2022, ISSN 1999-4923
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14010120

A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor

Autoren: Dezsi L, Meszaros T, Kozma GT, H-Velkei M, Olah CZ, Szabo M, Patko Zs, Fulop T, Hennies M, Szebeni M, Barta BA, Merkely B, Radovits T, and Szebeni J
Veröffentlicht in: GeroScience, Ausgabe 44(2), 2022, Seite(n) 597–618, ISSN 2509-2723
Herausgeber: Springer
DOI: 10.1007/s11357-021-00495-y

Zinc-Phthalocyanine-Loaded Extracellular Vesicles Increase Efficacy and Selectivity of Photodynamic Therapy in Co-Culture and Preclinical Models of Colon Cancer

Autoren: Pablo Lara, Ruben V. Huis in ‘t Veld, Carla Jorquera-Cordero, Alan B. Chan, Ferry Ossendorp, Luis J. Cruz
Veröffentlicht in: Pharmaceutics, Ausgabe 13/10, 2021, Seite(n) 1547, ISSN 1999-4923
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13101547

The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue

Autoren: Campos, Yaima; Fuentes, Gastón; Almirall, Amisel; Que, Ivo; Schomann, Timo; Chung, Chih Kit; Jorquera Cordero, Carla; Quintanilla Sierra, Luis; Rodríguez Cabello, José Carlos; Chan, Alan; Cruz, Luis
Veröffentlicht in: Pharmaceutics, Ausgabe 1, 2022, ISSN 1999-4923
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14020282

Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines

Autoren: Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Crommelin DJA and Dobrovolskaia MA
Veröffentlicht in: Nature Nanotechnology, Ausgabe 17(4), 2022, Seite(n) 337-346, ISSN 1748-3387
Herausgeber: Nature Publishing Group
DOI: 10.1038/s41565-022-01071-x

Eculizumab suppresses zymosan-induced release of inflammatory cytokinesIL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures:Relevance to cytokine storm in Covid-19

Autoren: Bakos T. Kozma GT, Szebeni J, Szénási G.
Veröffentlicht in: Biomedicine & Pharmacotherapy, Ausgabe 166, 2023, Seite(n) 115294, ISSN 0753-3322
Herausgeber: Elsevier Masson
DOI: 10.1016/j.biopha.2023.115294

Zymosan Particle-Induced Hemodynamic, Cytokine and Blood Cell Changes in Pigs: An Innate Immune Stimulation Model with Relevance to Cytokine Storm Syndrome and Severe COVID-19

Autoren: Kokeny G, Bakos T, Barta BA, Nagy GV, Meszaros T, Kozma GT, Szabo A, Szebeni J, Merkely B, Radovits T
Veröffentlicht in: International Journal of Molecular Sciences, Ausgabe 24, 2023, Seite(n) 18, ISSN 1661-6596
Herausgeber: MDPI
DOI: 10.3390/ijms24021138

Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion

Autoren: Gergely Milosevits,Tamás Mészáros, Erik Őrfi PharmD, Tamás Bakos, Miklós Garami, Gábor Kovács, László Dézsi, Péter Hamar, Balázs Győrffy, András Szabó, Gábor Szénási,János Szebeni.
Veröffentlicht in: Nanomedicine: Nanotechnology, Biology and Medicine, 2021, ISSN 1549-9634
Herausgeber: Elsevier BV
DOI: 10.1016/j.nano.2021.102366

Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm

Autoren: Gergely Tibor Kozma, Tamás Mészáros, Tamás Bakos, Mark Hennies, Dániel Bencze, Barbara Uzonyi, Balázs Győrffy, Edward Cedrone, Marina A. Dobrovolskaia, Mihály Józsi and János Szebeni.
Veröffentlicht in: Front. Immunol, Ausgabe 12, 2021, ISSN 1664-3224
Herausgeber: Front. Immunol
DOI: 10.3389/fimmu.2021.642860

To “PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

Autoren: Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA
Veröffentlicht in: Advanced Drug Delivery Reviews, Ausgabe 180, 2022, Seite(n) 22, ISSN 0169-409X
Herausgeber: Elsevier BV
DOI: 10.1016/j.addr.2021.114079

The Hypertensive Effect of Amphotericin B-Containing Liposomes (Abelcet) in Mice: Dissecting the Roles of C3a and C5a Anaphylatoxins, Macrophages and Thromboxane

Autoren: Orfi E, Hricisak L, Dezsi L, Hamar P, Benyo Z, Szebeni J, Szenasi G
Veröffentlicht in: Biomedicines, Ausgabe 10(7), 2022, Seite(n) 1764, ISSN 2227-9059
Herausgeber: MDPI AG
DOI: 10.3390/biomedicines10071764

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG

Autoren: Kozma TG, Meszaros T, Berenyi P, Facsko R, Patko Zs, Oláh Cs, Nagy J, Fulop T, Glatter K, Radovits T, Merkely B, Szebeni J.
Veröffentlicht in: Vaccine, Ausgabe 41, 2023, Seite(n) 4561-4570, ISSN 0264-410X
Herausgeber: Elsevier BV
DOI: 10.1016/j.vaccine.2023.06.009

Nanocarriers as a Tool for the Treatment of Colorectal Cancer

Autoren: Ana Luiza C. de S. L. Oliveira, Timo Schomann, Lioe-Fee de Geus-Oei, Ellen Kapiteijn, Luis J. Cruz, Raimundo Fernandes de Araújo Junior
Veröffentlicht in: Pharmaceutics, Ausgabe 13/8, 2021, Seite(n) 1321, ISSN 1999-4923
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13081321

Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA–Lipid Complexes

Autoren: Szebeni, J;Kiss, B;Bozo, T;Turjeman, K;Levi-Kalisman, Y;Barenholz, Y;Kellermayer, M
Veröffentlicht in: ACS NANO, Ausgabe 17, 2023, Seite(n) 13147-13157, ISSN 1936-0851
Herausgeber: American Chemical Society
DOI: 10.1021/acsnano.2c11904